Loading...
Docoh

Calithera Biosciences (CALA)

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California.

CALA stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$13.00
Low target
$8.00
High target
$18.00
HC Wainwright & Co.
Upgraded
Buy
$8.00
29 Aug 22
SVB Leerink
Maintains
Outperform
$18.00
16 Aug 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 Aug 22
30 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 42.1M 42.1M 42.1M 42.1M 42.1M 42.1M
Cash burn (monthly) 933.33K 4.2M 3.79M 8.8M 3.75M 5.04M
Cash used (since last report) 2.83M 12.74M 11.51M 26.69M 11.39M 15.29M
Cash remaining 39.27M 29.36M 30.59M 15.41M 30.71M 26.81M
Runway (months of cash) 42.1 7.0 8.1 1.8 8.2 5.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 22 Takeda Pharmaceutical Series A Convertible Preferred Stock Common Stock Other Acquire J Yes No 40.08 1,000,000 40.08M 1,000,000
1 Jul 22 Takeda Pharmaceutical Series A Convertible Preferred Stock Common Stock Other Dispose J Yes No 40.08 1,000,000 40.08M 0
1 Jun 22 Garland J. Scott Stock Option Common Stock Grant Acquire A No No 0.2 20,000 4K 20,000
1 Jun 22 Wise Blake Stock Option Common Stock Grant Acquire A No No 0.2 20,000 4K 20,000
1 Jun 22 Pakianathan Deepika Stock Option Common Stock Grant Acquire A No No 0.2 20,000 4K 20,000
1 Jun 22 Keith Orford Employee Stock Option Common Stock Grant Acquire A No No 0.2 20,000 4K 20,000
13F holders Current Prev Q Change
Total holders 56 58 -3.4%
Opened positions 12 11 +9.1%
Closed positions 14 20 -30.0%
Increased positions 13 19 -31.6%
Reduced positions 12 17 -29.4%
13F shares Current Prev Q Change
Total value 61.04M 72.09M -15.3%
Total shares 64.15M 62.44M +2.7%
Total puts 0 56.4K EXIT
Total calls 95.9K 163.1K -41.2%
Total put/call ratio 0.3
Largest owners Shares Value Change
TAK Takeda Pharmaceutical 14.82M $29.78M 0.0%
Primecap Management 10.73M $4.34M 0.0%
BVF 9.29M $3.76M +24.7%
Biotechnology Value Fund L P 7.45M $14.31M 0.0%
Citadel Advisors 4M $1.62M +13.3%
Vanguard 2.14M $863K -25.3%
Acadian Asset Management 1.98M $797K +6.5%
BLK Blackrock 1.93M $777K +0.4%
Renaissance Technologies 1.85M $749K +36.5%
Two Sigma Advisers 1.24M $502K +3.5%
Largest transactions Shares Bought/sold Change
BVF 9.29M +1.84M +24.7%
D. E. Shaw & Co. 239.54K -1.28M -84.2%
Alyeska Investment 1M +1M NEW
Affinity Asset Advisors 1M +1M NEW
Empery Asset Management 775.93K +775.93K NEW
Vanguard 2.14M -724.82K -25.3%
Jacobs Levy Equity Management 0 -721.26K EXIT
Anson Funds Management 0 -641.26K EXIT
Renaissance Technologies 1.85M +496.1K +36.5%
Dimensional Fund Advisors 0 -476.28K EXIT

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: attributable, Australia, blended, broker, brokerage, calibrated, consummation, denominator, DoR, duly, earliest, expressly, extinguishment, factor, feature, honored, IASLC, lieu, multicenter, multiplied, multiplying, NE, NM, noncash, numerator, Pacific, Pan, par, pro, proportion, purpose, rata, rearrangement, reclassification, reinstate, retroactive, spin, split, successor, surrender, survivor, synergistic, transmit, unexercised, uniformly, WCLC
Removed: AbbVie, Air, Bio, field, inclusion, Translate, utilize, Vertex